Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.48 |
| ▸ | CHRNG | P07510 | 2/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CHRND | Q07001 | 2/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461767 | 0.87 | GAA (0.45) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29888742 | 0.87 | GAA (0.45) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL27564348 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL11156933 | 0.86 | KDM4E (0.49) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23931566 | 0.84 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30012030 | 0.84 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL28578327 | 0.84 | L3MBTL1 (0.40) | SMN1; SMN2ALDH1A1MEN1NPC1KMT2A | |
| SCHEMBL1338330 | 0.84 | LMNA (0.52) | SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10606039 | 0.82 | SMN1; SMN2 (0.46) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1968428 | 0.82 | CES2 (0.53) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SLC6A2 480/4885SLC6A3 456/4885CHRNA1 369/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SLC6A2 430/4885SLC6A3 576/4885CHRNA1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.